Announced
Synopsis
Full-Life Technologies, a fully integrated global radiotherapeutics company, agreed to acquire Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer, for $245m. "The Focus-X acquisition perfectly leverages Full-Life's radiotechnology and development platform by adding two development ready compounds, including a lead with initial human data, a robust pipeline and world class peptide discovery capabilities," Lanny Sun, Full-Life Co-Founder, Chairman and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.